CLINICAL TRIALS
Pancreatic Cancer
About 84,000 people in the U.S. are living with pancreatic cancer, based on a 2018 estimate. In the U.S., only about 10% of patients live for at least 5 years after being diagnosed with pancreatic cancer, and about 48,000 patients were predicted to die of pancreatic cancer in 2021. Pancreatic cancer cases may be treatable with surgery when the cancer is diagnosed early, chemotherapy and/or radiation, or certain targeted therapies, but therapies that reliably improve survival have been elusive.
Ewing Sarcoma
Ewing sarcoma is a rare, aggressive cancer that originates in the bone and surrounding soft tissues. Typically diagnosed in children and adolescents, it is the second most common bone cancer in children and young adults between the ages of 10 and 20, with approximately 200-250 cases diagnosed in the U.S. each year. Although the exact cause is not fully understood, Ewing sarcoma is characterized by non-random chromosomal translocations producing fusion genes that encode aberrant transcription factors. New therapies are urgently needed, as current treatments often carry significant side effects and relapse rates are considerable, especially in cases of metastasis.
PARTNERING
As we continue to develop novel therapies to improve outcomes for patients. We are open to new partnerships with academic and scientific organizations.